Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis

Torben Lykke Sørensen; F Sellebjerg; C V Jensen; R M Strieter; R M Ransohoff

Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis

Torben Lykke Sørensen, F Sellebjerg, C V Jensen, R M Strieter, R M Ransohoff

Institut for Klinisk Medicin

104 Citationer (Scopus)

Abstract

Studies of chemokines in cerebrospinal fluid (CSF) of patients with active multiple sclerosis (MS) have indicated that specific chemokines may have important roles in disease pathogenesis. We previously reported that CSF concentrations of CXCL10 (previously known as IP-10) were elevated in MS patients in relapse, whilst levels of CCL2 (MCP-1) were reduced. Here, we report a serial analysis of CSF CXCL10 and CCL2 concentrations in 22 patients with attacks of MS or acute optic neuritis (ON) treated with methylprednisolone, and 26 patients treated with placebo in two randomized controlled trials. Chemokine concentrations were measured by enzyme linked immunosorbent assay (ELISA) in CSF obtained at baseline and after 3 weeks, and were compared with other measures of intrathecal inflammation. At baseline CSF concentrations of CCL2 were significantly lower in the patient group than in controls. The levels of CXCL10 were higher in the patient group than in controls but two outliers in the control group also had high CSF concentrations of CXCL10. The CSF concentrations of CXCL10 did not change over time or after treatment. The CSF concentration of CXCL10 was positively correlated with the CSF leukocyte count, the CSF concentration of neopterin, matrix metalloproteinase (MMP)-9, and intrathecal IgG and IgM synthesis. The concentration of CCL2 increased between baseline for 3 weeks in both groups, more distinctly so in patients treated with methylprednisolone. CCL2 correlated negatively with MMP-9 and IgG synthesis levels. CXCL10 may be involved in the maintenance of intrathecal inflammation whereas CCL2 correlates negatively with measures of inflammation, suggesting differential involvement of CXCL10 and CCL2 in CNS inflammation.

Originalsprog	Engelsk
Tidsskrift	European journal of neurology : the official journal of the European Federation of Neurological Societies
Vol/bind	8
Udgave nummer	6
Sider (fra-til)	665-72
Antal sider	8
ISSN	1351-5101
Status	Udgivet - nov. 2001

Citationsformater

Chemokines CXCL10 and CCL2 : differential involvement in intrathecal inflammation in multiple sclerosis. / Sørensen, Torben Lykke ; Sellebjerg, F; Jensen, C V et al.

I: European journal of neurology : the official journal of the European Federation of Neurological Societies, Bind 8, Nr. 6, 11.2001, s. 665-72.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning

@article{09b9e17b33484d96bab2cfb192300abd,

title = "Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis",

abstract = "Studies of chemokines in cerebrospinal fluid (CSF) of patients with active multiple sclerosis (MS) have indicated that specific chemokines may have important roles in disease pathogenesis. We previously reported that CSF concentrations of CXCL10 (previously known as IP-10) were elevated in MS patients in relapse, whilst levels of CCL2 (MCP-1) were reduced. Here, we report a serial analysis of CSF CXCL10 and CCL2 concentrations in 22 patients with attacks of MS or acute optic neuritis (ON) treated with methylprednisolone, and 26 patients treated with placebo in two randomized controlled trials. Chemokine concentrations were measured by enzyme linked immunosorbent assay (ELISA) in CSF obtained at baseline and after 3 weeks, and were compared with other measures of intrathecal inflammation. At baseline CSF concentrations of CCL2 were significantly lower in the patient group than in controls. The levels of CXCL10 were higher in the patient group than in controls but two outliers in the control group also had high CSF concentrations of CXCL10. The CSF concentrations of CXCL10 did not change over time or after treatment. The CSF concentration of CXCL10 was positively correlated with the CSF leukocyte count, the CSF concentration of neopterin, matrix metalloproteinase (MMP)-9, and intrathecal IgG and IgM synthesis. The concentration of CCL2 increased between baseline for 3 weeks in both groups, more distinctly so in patients treated with methylprednisolone. CCL2 correlated negatively with MMP-9 and IgG synthesis levels. CXCL10 may be involved in the maintenance of intrathecal inflammation whereas CCL2 correlates negatively with measures of inflammation, suggesting differential involvement of CXCL10 and CCL2 in CNS inflammation.",

keywords = "Anti-Inflammatory Agents, Chemokine CCL2, Chemokine CXCL10, Chemokines, CXC, Humans, Immunoglobulin G, Immunoglobulin M, Magnetic Resonance Imaging, Matrix Metalloproteinase 9, Methylprednisolone, Multiple Sclerosis, Neopterin",

author = "S{\o}rensen, {Torben Lykke} and F Sellebjerg and Jensen, {C V} and Strieter, {R M} and Ransohoff, {R M}",

year = "2001",

month = nov,

language = "English",

volume = "8",

pages = "665--72",

journal = "European Journal of Neurology",

issn = "1351-5101",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Chemokines CXCL10 and CCL2

T2 - differential involvement in intrathecal inflammation in multiple sclerosis

AU - Sørensen, Torben Lykke

AU - Sellebjerg, F

AU - Jensen, C V

AU - Strieter, R M

AU - Ransohoff, R M

PY - 2001/11

Y1 - 2001/11

N2 - Studies of chemokines in cerebrospinal fluid (CSF) of patients with active multiple sclerosis (MS) have indicated that specific chemokines may have important roles in disease pathogenesis. We previously reported that CSF concentrations of CXCL10 (previously known as IP-10) were elevated in MS patients in relapse, whilst levels of CCL2 (MCP-1) were reduced. Here, we report a serial analysis of CSF CXCL10 and CCL2 concentrations in 22 patients with attacks of MS or acute optic neuritis (ON) treated with methylprednisolone, and 26 patients treated with placebo in two randomized controlled trials. Chemokine concentrations were measured by enzyme linked immunosorbent assay (ELISA) in CSF obtained at baseline and after 3 weeks, and were compared with other measures of intrathecal inflammation. At baseline CSF concentrations of CCL2 were significantly lower in the patient group than in controls. The levels of CXCL10 were higher in the patient group than in controls but two outliers in the control group also had high CSF concentrations of CXCL10. The CSF concentrations of CXCL10 did not change over time or after treatment. The CSF concentration of CXCL10 was positively correlated with the CSF leukocyte count, the CSF concentration of neopterin, matrix metalloproteinase (MMP)-9, and intrathecal IgG and IgM synthesis. The concentration of CCL2 increased between baseline for 3 weeks in both groups, more distinctly so in patients treated with methylprednisolone. CCL2 correlated negatively with MMP-9 and IgG synthesis levels. CXCL10 may be involved in the maintenance of intrathecal inflammation whereas CCL2 correlates negatively with measures of inflammation, suggesting differential involvement of CXCL10 and CCL2 in CNS inflammation.

AB - Studies of chemokines in cerebrospinal fluid (CSF) of patients with active multiple sclerosis (MS) have indicated that specific chemokines may have important roles in disease pathogenesis. We previously reported that CSF concentrations of CXCL10 (previously known as IP-10) were elevated in MS patients in relapse, whilst levels of CCL2 (MCP-1) were reduced. Here, we report a serial analysis of CSF CXCL10 and CCL2 concentrations in 22 patients with attacks of MS or acute optic neuritis (ON) treated with methylprednisolone, and 26 patients treated with placebo in two randomized controlled trials. Chemokine concentrations were measured by enzyme linked immunosorbent assay (ELISA) in CSF obtained at baseline and after 3 weeks, and were compared with other measures of intrathecal inflammation. At baseline CSF concentrations of CCL2 were significantly lower in the patient group than in controls. The levels of CXCL10 were higher in the patient group than in controls but two outliers in the control group also had high CSF concentrations of CXCL10. The CSF concentrations of CXCL10 did not change over time or after treatment. The CSF concentration of CXCL10 was positively correlated with the CSF leukocyte count, the CSF concentration of neopterin, matrix metalloproteinase (MMP)-9, and intrathecal IgG and IgM synthesis. The concentration of CCL2 increased between baseline for 3 weeks in both groups, more distinctly so in patients treated with methylprednisolone. CCL2 correlated negatively with MMP-9 and IgG synthesis levels. CXCL10 may be involved in the maintenance of intrathecal inflammation whereas CCL2 correlates negatively with measures of inflammation, suggesting differential involvement of CXCL10 and CCL2 in CNS inflammation.

KW - Anti-Inflammatory Agents

KW - Chemokine CCL2

KW - Chemokine CXCL10

KW - Chemokines, CXC

KW - Humans

KW - Immunoglobulin G

KW - Immunoglobulin M

KW - Magnetic Resonance Imaging

KW - Matrix Metalloproteinase 9

KW - Methylprednisolone

KW - Multiple Sclerosis

KW - Neopterin

M3 - Journal article

C2 - 11784351

SN - 1351-5101

VL - 8

SP - 665

EP - 672

JO - European Journal of Neurology

JF - European Journal of Neurology

IS - 6

ER -

Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis

Abstract

Fingeraftryk

Citationsformater